Abstract
Keywords
Atezolizumab; Bevacizumab; Immunotherapy; Hepatocellular carcinoma
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Atezolizumab i bevacizumab per al tractament de primera línia del carcinoma hepatocel·lular (CHC). Barcelona: Servei Català de la Salut; 2022.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/8219This item appears in following collections
The following license files are associated with this item: